Skip to main content
. 2018 Jan 11;3(1):e97476. doi: 10.1172/jci.insight.97476

Figure 2. Mannosylated insulin analog GRI1 lowers glucose effectively without hypoglycemic incidence.

Figure 2

(A) STZ-induced diabetic rats received a single bolus of RHI or GRI1 with equivalent glucose-lowering potencies. n = 6 per group. (B and C) Scatter plots of individual animal glucose values corresponding to glucose values shown in A. (D) STZ-induced diabetic rats were implanted with a s.c. pump to deliver continuous infusion of optimized doses of GRI1 and RHI for 7 days to reach comparable glucose-lowering efficacy to each other. n = 8–9 per group. (E and F) Scatter plots of individual animal glucose values corresponding to glucose values shown in D. Results are shown as mean ± SEM of values and represent 3 independent experiments.